Enliven Therapeutics, Inc.
ELVN
$18.27
-$1.42-7.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.36% | -37.97% | -60.68% | -82.08% | -90.07% |
| Total Depreciation and Amortization | 6.73% | 11.31% | 18.11% | 27.16% | 38.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.75% | 87.30% | 44.00% | 114.38% | 170.04% |
| Change in Net Operating Assets | -424.13% | 141.45% | 92.54% | 192.69% | 219.86% |
| Cash from Operations | -19.46% | -20.27% | -51.99% | -49.87% | -91.01% |
| Capital Expenditure | 70.47% | 75.42% | 77.78% | 69.27% | 75.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 75.75% | 101.08% | 68.06% | -- | -- |
| Cash from Investing | 75.75% | 101.05% | 68.08% | -36,930.29% | -24,150.33% |
| Total Debt Issued | -- | -- | -200.00% | -200.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.33% | -61.69% | 208.79% | 207.27% | 41,115.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 95.91% | 80.52% | -289.08% |
| Cash from Financing | -43.16% | -59.76% | -60.53% | -62.97% | 13,123.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.56% | 317.46% | -186.73% | -174.36% | 171.34% |